SWOG 0016 A Phase III Trial Of CHOP Vs CHOP + Rituximab Vs CHOP + Iodine-131-Labeled Monoclonal Anti-B1 Antibody (Tositumomab) For Treatment Of Newly Diagnosed Follicular Non-Hodgkin's Lymphomas
SWOG 0106 A Phase III Study of the Addition of Mylotarg Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside followed by Consolidation and Subsequent Randomization to post-Consolidation Therapy with Mylotarg or No Additional Therapy for Patients under Age 61 With Previously Untreated De Novo AML
SWOG 0434 A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients with Relapsing or Resistant Multiple Myeloma Previously Treated with Bortezomib
SCRI LYM28 Brief Duration CNOP (or CVP) + Rituximab Followed by Maintenance Rituximab in Elderly/Poor Performance Status Patients with Aggressive B-Cell Lymphoma
Amgen 20060131 A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 versus Medical Standard of Care as Chronic Therapy for Non-Splenectomized Subjects with ITP
PACCT-1 Trial Assigning Individualized Options for Treatment
SWOG 0221 Phase III Trial of Continuous Schedule AC + G vs. Q2week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer
SWOG 0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
SWOG JMA.17R A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor either as Initial Therapy or after Tamoxifen (Including Those in the MA.17 Study)
SWOG 0430 Phase II Trial of Simple Oral Therapy (Continuous Oral Cyclophosphamide and Capecitabine) in Patients with Metastatic Breast Cancer
ACOSOG Z1031 A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
NSABP B36 A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of FEC to Four Cycles of AC in Patients with Node-Negative Breast Cancer
NSABP B40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on pCR of Adding Capecitabine or Gemcitabine to Docetaxel when Administered before AC +/- Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens
NSABP B42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an AI or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer
CALGB 80101 Phase III Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or Gastroesophageal Adenocarcinoma
NSABP R04 Trial Comparing Pre-Operative Radiation Treatment and Capecitabine with Pre-Operative Radiation Treatment and CVI of 5-FU in Treatment of Patients with Operable Cancer of the Rectum
Genentech ARIES An Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic of Locally Advanced and Unresectable Colorectal Cancer…(OBSERVATIONAL PHASE IV….colon and NSCLC)
ECOG E5202 Randomized Phase III Study Comparing 5-FU, Leucovorin, and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin, and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
NCCTG N0147 A Randomized Phase III trial of Oxaliplatin (OXAL) plus 5-Fluorouracil (5-FU)/Lecovorin(CF0 with or without Cetuximab (C225) after Curative resection for Patients with Stage III Colon Cancer
CALGB 80405 A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
ACOSOG Z9001 A Phase III Randomized Double-Blind Study of Adjuvant STI571 (GleevecTM) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumor (GIST)
RTOG 0522 A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas
ECOG 1302 Phase III Randomized, Placebo Controlled Trial of Docetaxel Plus ZD1839 in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck
Genentech ATLAS A Phase III Trial of Bevacizumab in Combination with First or Second Line Therapy in Subjects with Treated Brain Metastases due to Non-Squamos NSCLC
Pfizer A8501003 A Randomized Phase 2 Trial of Paclitaxel, Carboplatin, and Bevacizumab with or without PF-3512676 as First Line Treatment of Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
SWOG 0429 A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer
SWOG E5597 Phase III Chemoprevention Trial of Selenium Supplementation in Resected Stage I NSCLC
ECOG E2603 A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma
SWOG 0008 Phase III Trial of High Dose Interferon Alpha-2b Versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients With High Risk Melanoma
Novacea ASCENT 2 A Phase III Randomized, Open-Label Study Evaluating DN-101 in Combination with Docetaxel in Androgen-Independent Prostate Cancer (AIPC)
ECOG 2805 A Randomized, Double Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
SCRI UNKPRI-12 Phase III Randomized Comparison of Gemcitabine/Irinotecan Followed by Iressa versus Paclitaxel/Carboplatin/Etoposide Followed by Iressa in First Line Treatment of Patients with Cancer of Unknown Primary